Vertex Cystic Fibrosis Forecast Brightens, With Gloomy Prospects For Competition

Vertex continued its growth story in cystic fibrosis during 2017. It also chose a pair of candidates for Phase III triple combination development, threatening to virtually seal off market entry to others.